|
|
Post by boca1girl on Dec 28, 2016 14:32:41 GMT -5
CNBC - within the last hour, CNBC announced that diabeties was the leading disease for health care spending in 2016, followed by heart disease. Nothing more, just that short statement. Too bad MNKD can't get coverage on Dr. Oz or any of the other tv talk shows. I've written to the Dr. Oz show suggesting they do a segment on Afrezza, but never got any response. Maybe I should write to CNBC to do a follow up to today's comments and suggest they do a story on Afrezza.
|
|
|
|
Post by otherottawaguy on Dec 28, 2016 14:50:26 GMT -5
I was just looking at the Dr Oz site looking for references to Afrezza. Had the search results return 4 records if anyone is interested. Did not see anyway of submitting story ideas.
Wonder what would happen if 2600 members of this board each email one suggestion about Afrezza...
OOG
|
|
|
|
Post by careful2invest on Dec 28, 2016 16:12:18 GMT -5
CNBC - within the last hour, CNBC announced that diabeties was the leading disease for health care spending in 2016, followed by heart disease. Nothing more, just that short statement. Too bad MNKD can't get coverage on Dr. Oz or any of the other tv talk shows. I've written to the Dr. Oz show suggesting they do a segment on Afrezza, but never got any response. Maybe I should write to CNBC to do a follow up to today's comments and suggest they do a story on Afrezza. It couldn't hurt!! Knowing that a key element to minimize the damage caused by diabetes is that of maintaining a lower A1C, And knowing that AFREZZA along with Tresiba and even Lantus can acheive this, One would think that insurance companies would be forward thinking enough to recognize AFREZZA'S true value! Doesn't it seem obvious? GLTA TRUE LONGS! |
|
|
|
Post by mannmade on Dec 31, 2016 13:21:13 GMT -5
Dr. Oz and The Doctors have both been tried as has been The Today Show etc. Shows like OZ require a significant placement fee plus a television ad buy and a digital media ad buy. Also once you pay for the integration it is no longer a qualified news story and is now a form of advertising subject to all the FDA rules and regs. MannKind has explored many options over the years to get the word out while trying to stay focused on the more basic core business and the blocking and tackling required to run it.
As for the Today Show you either pay a fee as in above or you must qualify independently as a story of organic interest to the news division which unfortunately in the eyes of the current segment producers and story producers AFREZZA does not for some reason. Which I personally find strange especially during November.
I think one thing that is greatly overlooked despite lower than favorable script numbers it is a very well run company. Quality control is high, you never hear any negative issues from patients or PWD except perhaps for insurance issues, etc which are out of their control.
|
|
|
|
Post by nylefty on Dec 31, 2016 14:33:45 GMT -5
Great post, mannmade. Dr. Oz has a well-deserved reputation as a snake oil salesman.
|
|
|
|
Post by boca1girl on Jan 3, 2017 12:43:49 GMT -5
How about 60 Minutes? I think the general public would value a story if they produced one. The reaction to the Lumber Liquidators story last year was harsh and swift. If a good news story on Afrezza was presented, I bet it would drive patient questions to doctors.
|
|
|
|
Post by dreamboatcruise on Jan 5, 2017 15:02:36 GMT -5
CNBC - within the last hour, CNBC announced that diabeties was the leading disease for health care spending in 2016, followed by heart disease. Nothing more, just that short statement. Too bad MNKD can't get coverage on Dr. Oz or any of the other tv talk shows. I've written to the Dr. Oz show suggesting they do a segment on Afrezza, but never got any response. Maybe I should write to CNBC to do a follow up to today's comments and suggest they do a story on Afrezza. It couldn't hurt!! Knowing that a key element to minimize the damage caused by diabetes is that of maintaining a lower A1C, And knowing that AFREZZA along with Tresiba and even Lantus can acheive this, One would think that insurance
companies would be forward thinking enough to recognize AFREZZA'S true value! Doesn't it seem obvious? GLTA TRUE LONGS! Insurance companies do not necessarily take a long term view of cost/benefit... and there are real reasons for it. First... wall street is primarily concerned about short term performance, and executives are usually judged on it. Second, insurance companies know that many of their covered lives will not be with them long term such that paying more upfront to avoid costs in the future may well simply be subsidizing the profits of their competitors... not to mention that since Medicare covers a large number of people in retirement, insurers paying more for middle age T2's to avoid progression miss out on future savings once these patients transition to Medicare. These facts contribute to the rationale for health care reform. How do we incentivize insurers to really try to slow down diabetes progression rather than maximizing short term profit while rationalizing that "once they need an amputation, they well not be our cost". Frankly, I don't think they really discuss the detailed decisions in such stark terms, but their processes for evaluating decisions are simply set up to act in short term interest, so the outcome is the same. |
|
|
|
Post by boca1girl on Jan 6, 2017 8:57:01 GMT -5
I agree with your comments 100%. Unfortunately for all of us, our health care is governed buy short term profit motivations.
I'm not a big proponent of big government, but we need some sort of "Medicare for Everyone" like program and eliminate all "middle men" (pharmacy benefit management, insurance) who are driven by profits from our illnesses. But I don't believe I will see this change in mindset in my lifetime.
I heard Mike's reason for not lowering the price for Afrezza, but I disagree. If I was running the company, I would make the price very attractive and drive adoption/demand with support from the short term profit driven "middle men".
|
|
